Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Pivekimab Sunirine |
| Synonyms | |
| Therapy Description |
IMGN632 is an antibody-drug conjugate (ADC) comprising an anti-CD123 (IL3RA) antibody linked to a DNA alkylating indolinobenzodiazepine pseudodimer, which may induce cytotoxicity in cells expressing CD123 (IL3RA) (PMID: 29661755, PMID: 30361418). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Pivekimab Sunirine | IMGN 632|IMGN-632|IMGN632 | CD123 (IL3RA) Antibody 14 | Pivekimab Sunirine is an antibody-drug conjugate (ADC) comprising an anti-CD123 (IL3RA) antibody linked to a DNA alkylating indolinobenzodiazepine pseudodimer, which may induce cytotoxicity in cells expressing CD123 (IL3RA) (PMID: 29661755, PMID: 30361418). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03386513 | Phase Ib/II | Pivekimab Sunirine | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |
| NCT04086264 | Phase Ib/II | Pivekimab Sunirine Pivekimab Sunirine + Venetoclax Azacitidine + Pivekimab Sunirine Azacitidine + Pivekimab Sunirine + Venetoclax | IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | 0 |